US5122526A
(en)
*
|
1987-03-31 |
1992-06-16 |
Research Triangle Institute |
Camptothecin and analogs thereof and pharmaceutical compositions and method using them
|
US5053512A
(en)
*
|
1987-04-14 |
1991-10-01 |
Research Triangle Institute |
Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives
|
US5364858A
(en)
*
|
1987-03-31 |
1994-11-15 |
Research Triangle Institute |
Camptothecin analogs as potent inhibitors of topoisomerase I
|
US5227380A
(en)
*
|
1987-03-31 |
1993-07-13 |
Research Triangle Institute |
Pharmaceutical compositions and methods employing camptothecins
|
US5106742A
(en)
*
|
1987-03-31 |
1992-04-21 |
Wall Monroe E |
Camptothecin analogs as potent inhibitors of topoisomerase I
|
US5049668A
(en)
*
|
1989-09-15 |
1991-09-17 |
Research Triangle Institute |
10,11-methylenedioxy-20(RS)-camptothecin analogs
|
US5122606A
(en)
*
|
1987-04-14 |
1992-06-16 |
Research Triangle Institute |
10,11-methylenedioxy camptothecins
|
US5340817A
(en)
*
|
1987-04-14 |
1994-08-23 |
Research Triangle Institute |
Method of treating tumors with anti-tumor effective camptothecin compounds
|
US5180722A
(en)
*
|
1987-04-14 |
1993-01-19 |
Research Triangle Institute |
10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs
|
US4939255A
(en)
*
|
1987-06-24 |
1990-07-03 |
Daiichi Pharmaceutical Co., Ltd. |
Hexa-cyclic camptothecin derivatives
|
US5552154A
(en)
|
1989-11-06 |
1996-09-03 |
The Stehlin Foundation For Cancer Research |
Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
|
JP2684104B2
(ja)
*
|
1990-02-09 |
1997-12-03 |
株式会社ヤクルト本社 |
新規なカンプトテシン誘導体
|
DE69131775T2
(de)
*
|
1990-09-28 |
2000-04-20 |
Smithkline Beecham Corp. |
Verfahren zur Herstellung wasserlöslicher Camptothecinanaloge, sowie die Verbindungen 10-Hydroxy-11-C(1-6)-alkoxycamptothecin
|
US5883255A
(en)
*
|
1990-10-31 |
1999-03-16 |
Smithkline Beecham Corporation |
Substituted indolizino 1,2-b!quinolinones
|
DE69232852T2
(de)
*
|
1991-02-21 |
2003-09-04 |
Smithkline Beecham Corp., Philadelphia |
Verwendung von topotecan in der behandlung von nichtkleinzelligen lungenkarzinomen
|
ATE476182T1
(de)
*
|
1991-02-21 |
2010-08-15 |
Glaxosmithkline Llc |
Pharmazeutische zusammensetzung zur verwendung in der behandlung von eierstockkrebs
|
JPH06505487A
(ja)
*
|
1991-02-21 |
1994-06-23 |
スミスクライン・ビーチャム・コーポレイション |
食道癌の治療用医薬組成物
|
EP0540099B1
(fr)
*
|
1991-10-29 |
1996-04-17 |
Glaxo Wellcome Inc. |
Dérivés de camptothécine solubles dans l'eau
|
US5559235A
(en)
*
|
1991-10-29 |
1996-09-24 |
Glaxo Wellcome Inc. |
Water soluble camptothecin derivatives
|
ATE247471T1
(de)
*
|
1991-11-15 |
2003-09-15 |
Smithkline Beecham Corp |
Cisplatin und topotecan enthaltende zusammensetzung als antitumor.
|
JPH07501818A
(ja)
*
|
1991-12-10 |
1995-02-23 |
スミスクライン・ビーチャム・コーポレイション |
結腸直腸癌の治療
|
US6080751A
(en)
*
|
1992-01-14 |
2000-06-27 |
The Stehlin Foundation For Cancer Research |
Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
|
US5446047A
(en)
*
|
1992-07-23 |
1995-08-29 |
Sloan-Kettering Institute For Cancer Research |
Camptothecin analogues
|
US5391745A
(en)
*
|
1992-07-23 |
1995-02-21 |
Sloan-Kettering Institute For Cancer Research |
Methods of preparation of camptothecin analogs
|
WO1994004160A1
(fr)
*
|
1992-08-21 |
1994-03-03 |
Dana Farber Cancer Institute |
Traitement d'infections virales chez l'homme
|
US5614549A
(en)
*
|
1992-08-21 |
1997-03-25 |
Enzon, Inc. |
High molecular weight polymer-based prodrugs
|
US5342947A
(en)
*
|
1992-10-09 |
1994-08-30 |
Glaxo Inc. |
Preparation of water soluble camptothecin derivatives
|
AP9300587A0
(en)
*
|
1992-11-12 |
1995-05-05 |
Glaxo Inc |
Water soluble camptothecin derivatives.
|
US5674872A
(en)
*
|
1993-08-20 |
1997-10-07 |
Smithkline Beecham Corporation |
Treatment of ovarian cancer
|
WO1995011020A1
(fr)
*
|
1993-10-20 |
1995-04-27 |
Enzon, Inc. |
Substances taxoides substituees en position 2' et/ou 7'
|
US5880131A
(en)
*
|
1993-10-20 |
1999-03-09 |
Enzon, Inc. |
High molecular weight polymer-based prodrugs
|
US5436243A
(en)
*
|
1993-11-17 |
1995-07-25 |
Research Triangle Institute Duke University |
Aminoanthraquinone derivatives to combat multidrug resistance
|
US5447936A
(en)
*
|
1993-12-22 |
1995-09-05 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
|
GB9402934D0
(en)
*
|
1994-02-16 |
1994-04-06 |
Erba Carlo Spa |
Camptothecin derivatives and process for their preparation
|
US5468754A
(en)
*
|
1994-04-19 |
1995-11-21 |
Bionumerik Pharmaceuticals, Inc. |
11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof
|
EP0758237B1
(fr)
*
|
1994-04-28 |
2003-08-27 |
Bionumerik Pharmaceuticals, Inc. |
Formulation stable sous forme lactone de camptothecine ou 7-ethyle camptothecine dans du dimethylisosorbide ou du dimethylacetamide
|
US5597829A
(en)
*
|
1994-05-09 |
1997-01-28 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of camptothecin and methods for uses thereof
|
US5604233A
(en)
*
|
1994-04-28 |
1997-02-18 |
Bionumerik Pharmaceuticals, Inc. |
Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof
|
US5491237A
(en)
|
1994-05-03 |
1996-02-13 |
Glaxo Wellcome Inc. |
Intermediates in pharmaceutical camptothecin preparation
|
US5834442A
(en)
*
|
1994-07-07 |
1998-11-10 |
Barbara Ann Karmanos Cancer Institute |
Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
|
US5646159A
(en)
*
|
1994-07-20 |
1997-07-08 |
Research Triangle Institute |
Water-soluble esters of camptothecin compounds
|
US6504029B1
(en)
*
|
1995-04-10 |
2003-01-07 |
Daiichi Pharmaceutical Co., Ltd. |
Condensed-hexacyclic compounds and a process therefor
|
GB9510716D0
(en)
*
|
1995-05-26 |
1995-07-19 |
Pharmacia Spa |
Substituted camptothecin derivatives and process for their preparation
|
US5670500A
(en)
*
|
1995-05-31 |
1997-09-23 |
Smithkline Beecham Corporation |
Water soluble camptothecin analogs
|
US5663177A
(en)
*
|
1995-05-31 |
1997-09-02 |
Smithkline Beecham Corporation |
Water soluble camptothecin analogs
|
EP0835303A4
(fr)
*
|
1995-06-07 |
2000-09-13 |
Univ Jefferson |
Agents antifongiques et leurs procedes d'identification et d'utlisation
|
WO1997019085A1
(fr)
*
|
1995-11-22 |
1997-05-29 |
Research Triangle Institute |
Composes de camptothecine a proprietes combinees d'inhibition de la topoisomerase i et d'alkylation de l'adn
|
US6395541B1
(en)
|
1996-05-23 |
2002-05-28 |
The Rockefeller University |
Methods for the identification of compounds capable of inhibiting HIV-1 viral replication employing murine cell lines expressing human topoisomerase I
|
AU718799C
(en)
*
|
1996-08-19 |
2004-02-12 |
Bionumerik Pharmaceuticals, Inc. |
Highly lipophilic camptothecin derivatives
|
US6013505A
(en)
*
|
1996-10-08 |
2000-01-11 |
Smithkline Beecham Corporation |
Topoisomerase I
|
US5962303A
(en)
*
|
1996-10-15 |
1999-10-05 |
Smithkline Beecham Corporation |
Topoisomerase III
|
US6025156A
(en)
*
|
1996-10-15 |
2000-02-15 |
Smithkline Beecham Corporation |
Topoisomerase III
|
US6559309B2
(en)
|
1996-11-01 |
2003-05-06 |
Osi Pharmaceuticals, Inc. |
Preparation of a camptothecin derivative by intramolecular cyclisation
|
ES2262223T3
(es)
*
|
1997-02-14 |
2006-11-16 |
Bionumerik Pharmaceuticals, Inc. |
Derivados de camptotecina altamente lipofilos.
|
US6207673B1
(en)
*
|
1997-03-12 |
2001-03-27 |
The University Of North Carolina At Chapel Hill |
Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
|
ID23424A
(id)
|
1997-05-14 |
2000-04-20 |
Bayer Ag |
Glikokonjugat dari 20(s)-kamptotesin
|
US6046209A
(en)
*
|
1997-05-27 |
2000-04-04 |
Smithkline Beecham Corporation |
Water soluble camptothecin analogs
|
CA2243363C
(fr)
*
|
1997-07-17 |
2002-01-29 |
Kuraray Co., Ltd. |
Procede pour produire des chromanes
|
US6011042A
(en)
*
|
1997-10-10 |
2000-01-04 |
Enzon, Inc. |
Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
|
US6214821B1
(en)
|
1998-03-05 |
2001-04-10 |
Washington State University Research Foundation |
Methods and composition for the inhibition of cancer cells
|
NZ509859A
(en)
*
|
1998-08-05 |
2003-09-26 |
Aventis Pharma S |
Use of camptothecin derivatives, with reduced gastrointestinal toxicity
|
WO2001024763A2
(fr)
|
1999-10-01 |
2001-04-12 |
Immunogen, Inc. |
Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
|
FR2801309B1
(fr)
*
|
1999-11-18 |
2002-01-04 |
Adir |
Nouveaux composes analogues de la camptothecine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
US6288072B1
(en)
*
|
1999-12-29 |
2001-09-11 |
Monroe E. Wall |
Camptothecin β-alanine esters with topoisomerase I inhibition
|
WO2001062235A2
(fr)
|
2000-02-28 |
2001-08-30 |
Aventis Pharma S.A. |
Composition comprenant la camptothecine et un derive de pyrimidine et destinee a etre utilisee dans le traitement du cancer
|
US6545010B2
(en)
|
2000-03-17 |
2003-04-08 |
Aventis Pharma S.A. |
Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
|
US6548488B2
(en)
|
2000-03-17 |
2003-04-15 |
Aventis Pharma S.A. |
Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
|
AR027687A1
(es)
*
|
2000-03-22 |
2003-04-09 |
Yakult Honsha Kk |
Procedimiento para preparar camptotecina
|
US6486320B2
(en)
|
2000-09-15 |
2002-11-26 |
Aventis Pharma S.A. |
Preparation of camptothecin and of its derivatives
|
MXPA03002882A
(es)
|
2000-10-27 |
2004-12-03 |
Aventis Pharma Sa |
Una combinacion que contiene camptotecina y un derivado de estilbeno para el tratamiento del cancer.
|
WO2002040653A2
(fr)
*
|
2000-11-14 |
2002-05-23 |
Emerald Biostructures, Inc. |
Structures et methodes de designation de la topoisomerase i
|
IL163666A0
(en)
|
2002-02-22 |
2005-12-18 |
New River Pharmaceuticals Inc |
Active agent delivery systems and methods for protecting and administering active agents
|
WO2003080075A1
(fr)
*
|
2002-03-26 |
2003-10-02 |
Cci Corporation |
Ameliorant pour le traitement chimique du cancer
|
ITRM20020306A1
(it)
*
|
2002-05-31 |
2003-12-01 |
Sigma Tau Ind Farmaceuti |
Esteri in posizione 20 di camptotecine.
|
US8129330B2
(en)
*
|
2002-09-30 |
2012-03-06 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US20040062748A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Mountain View Pharmaceuticals, Inc. |
Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
|
US8034831B2
(en)
*
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
WO2004055020A1
(fr)
*
|
2002-12-16 |
2004-07-01 |
Council Of Scientific And Industrial Research |
Procede de preparation directe d'analogues de 5-alcoxy et de 5-acyloxy de camptothecines ou de mappicines cetones
|
FR2852606A1
(fr)
*
|
2003-03-18 |
2004-09-24 |
Inst Nat Sante Rech Med |
Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
|
AU2003223109A1
(en)
*
|
2003-03-31 |
2004-10-25 |
Council Of Scientific And Industrial Research |
Process for preparing topotecan from 10-hydroxy-4-(s) camptothecin
|
CN100406460C
(zh)
*
|
2003-11-10 |
2008-07-30 |
中国科学院上海药物研究所 |
喜树碱的新衍生物、制备方法和用途
|
AR046579A1
(es)
*
|
2003-11-12 |
2005-12-14 |
Smithkline Beecham Corp |
Compuesto cristalino de topotecan, composicion farmaceutica que lo comprende, procedimiento para prepararlo y su uso para preparar dicha composicion farmaceutica
|
DE602005027673D1
(de)
|
2004-03-05 |
2011-06-09 |
Vegenics Pty Ltd |
Materialien und verfahren für wachstumsfaktorbindende konstrukte
|
RU2408387C2
(ru)
|
2004-04-27 |
2011-01-10 |
Веллстат Байолоджикс Корпорейшн |
Лечение злокачественного новообразования с применением вирусов и камптотецинов
|
US20050267141A1
(en)
|
2004-05-28 |
2005-12-01 |
Phytogen Life Sciences Inc. |
Process to prepare camptothecin derivatives
|
US20050272757A1
(en)
*
|
2004-06-04 |
2005-12-08 |
Phytogen Life Sciences Inc. |
Process to prepare camptothecin derivatives and novel intermediate and compounds thereof
|
US7122700B2
(en)
*
|
2004-07-30 |
2006-10-17 |
Xerox Corporation |
Arylamine processes
|
WO2006069344A2
(fr)
|
2004-12-22 |
2006-06-29 |
Rutgers, The State University Of New Jersey |
Hydrogels a liberation regulee
|
WO2012050591A1
(fr)
|
2010-10-15 |
2012-04-19 |
Rutgers, The State University Of New Jersey |
Formulation d'hydrogel pour une administration dermique et oculaire
|
CA2594474C
(fr)
|
2005-01-21 |
2016-03-29 |
Astex Therapeutics Limited |
Composes pharmaceutiques
|
JP5106098B2
(ja)
*
|
2005-02-28 |
2012-12-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
スルホンアミド化合物の抗癌剤との新規併用
|
EP1907015B1
(fr)
*
|
2005-07-14 |
2012-01-11 |
Wellstat Biologics Corporation |
Traitement anticancéreux à l'aide de virus, fluoropyrimidines et camptothécines
|
WO2007042799A1
(fr)
*
|
2005-10-10 |
2007-04-19 |
Cipla Limited |
Nouvelles formes cristallines
|
TW200731990A
(en)
*
|
2005-12-16 |
2007-09-01 |
Sonus Pharma Inc |
Lipophilic anticancer drug compounds, compositions, and related methods
|
US7547785B2
(en)
|
2005-12-26 |
2009-06-16 |
Dr. Reddy's Laboratories Limited |
Process for preparing topotecan
|
WO2007085370A1
(fr)
*
|
2006-01-25 |
2007-08-02 |
Heidelberg Pharma Ag |
Dérivés d’esters lipidiques de la 9-(dimethylamino)methyl-10-hydroxycamptothecine
|
CN101033230B
(zh)
*
|
2006-03-10 |
2010-12-08 |
中国科学院上海药物研究所 |
一类喜树碱衍生物及其应用
|
US8410045B2
(en)
|
2006-03-30 |
2013-04-02 |
Drais Pharmaceuticals, Inc. |
Camptothecin-peptide conjugates and pharmaceutical compositions containing the same
|
WO2007127839A2
(fr)
*
|
2006-04-26 |
2007-11-08 |
The Regents Of The University Of California |
Compositions et méthodes pour l'administration de neurothérapeutiques de haut poids moléculaire améliorée par convection
|
WO2008021549A2
(fr)
*
|
2006-08-18 |
2008-02-21 |
Sidney Kimmel Cancer Center |
Procédés et compositions pour la suppression de tumeurs modulées par la topoisomérase i
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
EP2073807A1
(fr)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Combinaisons pharmaceutiques
|
US7977483B2
(en)
*
|
2007-04-11 |
2011-07-12 |
Scinopharm Taiwan, Ltd. |
Process for making topotecan
|
US20080255175A1
(en)
*
|
2007-04-16 |
2008-10-16 |
Lam Marina K |
Anti-cancer agents, compositions and methods of treating cancers
|
CN101730702B
(zh)
*
|
2007-04-19 |
2012-07-18 |
台湾神隆股份有限公司 |
盐酸拓扑替康的晶形及其制备方法
|
US8026249B2
(en)
*
|
2007-09-14 |
2011-09-27 |
Deutena Pharmaceuticals, Inc. |
Deuterium-enriched topotecan
|
ITMI20072268A1
(it)
|
2007-12-04 |
2009-06-05 |
Antibioticos Spa |
Polimorfi cristallini di topotecan cloridrato con elevato grado di purezza e metodi per la loro preparazione
|
KR101600114B1
(ko)
*
|
2008-05-29 |
2016-03-04 |
니혼 마이크로바이오팜 가부시키가이샤 |
캠토테신 유도체의 제조 방법
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
TW201031675A
(en)
|
2008-12-23 |
2010-09-01 |
Pharmasset Inc |
Synthesis of purine nucleosides
|
EP2376514A2
(fr)
*
|
2008-12-23 |
2011-10-19 |
Pharmasset, Inc. |
Analogues de nucléoside
|
EP2376088B1
(fr)
*
|
2008-12-23 |
2017-02-22 |
Gilead Pharmasset LLC |
Phosphoramidates de nucléosides de type 2-amino-purine 6-O-substituée
|
EP2547359B1
(fr)
|
2010-03-15 |
2016-03-09 |
The Board of Trustees of the University of Illionis |
Inhibiteurs des interactions de liaison de sous unité alpha d'intégrine à-de protéine g
|
UY33311A
(es)
|
2010-03-31 |
2011-10-31 |
Pharmasset Inc |
Fosforamidatos de nucleosidos
|
RU2447076C1
(ru)
*
|
2010-12-09 |
2012-04-10 |
Закрытое Акционерное Общество "Фарм-Синтез" |
Способ получения топотекана
|
WO2012083197A1
(fr)
|
2010-12-17 |
2012-06-21 |
Nektar Therapeutics |
Conjugués polymères hydrosolubles de topotécan
|
US8709420B2
(en)
|
2010-12-17 |
2014-04-29 |
Glaxosmithkline Intellectual Property Limited |
Pharmaceutical combination of pazopanib and topotecan to treat neuroblastoma, osteosarcoma, and rhabdomyosarcoma in a human
|
WO2012087943A2
(fr)
|
2010-12-20 |
2012-06-28 |
The Regents Of The University Of Michigan |
Inhibiteurs de l'interaction de liaison entre le récepteur du facteur de croissance épidermique et la protéine de choc thermique 90
|
JP2014504638A
(ja)
|
2011-02-01 |
2014-02-24 |
グラクソスミスクライン インテレクチュアル プロパティ リミテッド |
組合せ
|
EP2750683B2
(fr)
|
2011-10-03 |
2021-01-06 |
Croda International PLC |
Nanoparticules, leur procédé de préparation et leur utilisation comme support pour des molécules amphipatiques ou hydrophobes dans des domaines de la médecine, comprenant le traitement du cancer et des composés alimentaires
|
PL235836B1
(pl)
*
|
2012-10-25 |
2020-11-02 |
Inst Chemii Organicznej Polskiej Akademii Nauk |
Pochodne kamptotecyny, sposób ich otrzymywania i zastosowanie
|
CN103113381B
(zh)
*
|
2013-02-26 |
2014-12-10 |
大连理工大学 |
系列水溶性羟基喜树碱环烷胺醇衍生物及其制法与用途
|
WO2014163558A1
(fr)
|
2013-04-01 |
2014-10-09 |
Moreinx Ab |
Nanoparticules, constituées de stérol et de saponine de quillaja saponaria molina, leur procédé de préparation et leur utilisation comme support pour des molécules amphipathiques ou hydrophobes dans le domaine médical, notamment pour le traitement du cancer, et composés alimentaires
|
CN107683289B
(zh)
|
2015-01-26 |
2021-08-06 |
芝加哥大学 |
IL13Rα2结合剂和其在癌症治疗中的用途
|
CN107835820B
(zh)
|
2015-01-26 |
2021-10-15 |
芝加哥大学 |
识别癌症特异性IL13Rα2的CAR T细胞
|
AU2016326747A1
(en)
|
2015-09-25 |
2018-03-01 |
Zy Therapeutics Inc. |
Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
|
CN109195593A
(zh)
|
2016-03-15 |
2019-01-11 |
奥莱松基因组股份有限公司 |
用于治疗实体瘤的lsd1抑制剂的组合
|
SI3622953T1
(sl)
*
|
2016-05-17 |
2021-05-31 |
Scandion Oncology A/S |
Kombinirano zdravljenje raka
|
EP3664844A1
(fr)
|
2017-08-07 |
2020-06-17 |
Amgen Inc. |
Traitement du cancer du sein triple négatif ou du cancer colorectal comportant des métastases hépatiques par un anticorps anti-pd-l1 et un virus oncolytique
|
EP3669890A1
(fr)
|
2018-12-18 |
2020-06-24 |
Croda International PLC |
Nanoparticules filamenteuses ayant un effet d'adjuvant de vaccin
|
EP3941944A4
(fr)
|
2019-03-20 |
2022-11-30 |
The Regents of the University of California |
Anticorps de claudin-6 bispécifiques
|
CA3134055A1
(fr)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Anticorps anti-claudine-6 et conjugues de medicaments
|
US20220160872A1
(en)
|
2019-04-09 |
2022-05-26 |
The Board Of Trustees Of The University Of Illinois |
Drug Adsorbed Highly Porous Activated Carbon for Enhanced Drug Delivery
|
AU2020266083A1
(en)
|
2019-04-30 |
2021-09-23 |
Instituto de Medicina Molecular João Lobo Antunes |
Rank pathway inhibitors in combination with CDK inhibitors
|
JP2022538829A
(ja)
|
2019-06-24 |
2022-09-06 |
アムジェン インコーポレイテッド |
癌治療のためのSIRPγの阻害
|
US20220265659A1
(en)
|
2019-09-02 |
2022-08-25 |
Inserm (Institut National De La Santé Et De Al Recherche Médicale) |
Methods and compositions for treating pax6-deficiency related disease
|
WO2023220641A2
(fr)
|
2022-05-11 |
2023-11-16 |
Juno Therapeutics, Inc. |
Méthodes et utilisations associées à une thérapie par lymphocytes t et leur production
|
CN116478174A
(zh)
*
|
2022-07-29 |
2023-07-25 |
杭州爱科瑞思生物医药有限公司 |
喜树碱衍生物及其制备方法和应用
|
CN117599058A
(zh)
*
|
2023-03-09 |
2024-02-27 |
兰州大学 |
喜树碱类衍生物在制备治疗膀胱癌药物中的应用
|